Rameen Beroukhim got his PhD at the University of Cambridge in 1996 and his MD at the University of California in 2000. He is currently a physician in the Department of Medical Oncology at the Dana-Farber Cancer Institute, an associate physician in medical oncology at Brigham and Women’s Hospital and an assistant professor of medicine at Harvard Medical School.
Dr. Beroukhim co-chairs the International Cancer Genome Consortium effort to characterize structural alterations across 2800 cancer whole genomes. He is also the lead principal investigator of a multi-investigator R01 grant and of individual and multi-PI foundation- and industry-funded grants. His administrative roles include numerous committees, working groups and grant review activities, such as admissions committees for the HMS Bioinformatics and Integrative Genomics (BIG), MD-PhD programs and the MGH/DFCI neurooncology fellowship program, the Ethics Advisory Committee at DFCI, and the Broad Institute Cancer Program Steering Committee. He has been ad hoc reviewer of 31 well-renowned scientific journals, and is at the editorial review board of Neurooncology since 2013.
Dr. Beroukhim’s scientific focus is on the genomic features of oncogenesis and cancer progression in brain and other cancers, and the implications of these in identifying novel cancer dependencies, therapeutic strategies, and biomarkers. He has 154 peer-reviewed articles, including 16 last- or co-last author papers, of which four were published in Nature Genetics and Cell.